Effect and mechanism of Jianpi Yishen Formula on muscle consumption and survival time in mouse model with lung cancer cachexia

JI Zhao-yi; ZHU Jian; ZHU Xiao-yun; JIAO Yong-zheng; WU Jie

doi:10.16025/j.1674-1307.2023.11.011

您当前的位置：

首页 >

文章列表页 >

Effect and mechanism of Jianpi Yishen Formula on muscle consumption and survival time in mouse model with lung cancer cachexia

更新时间：2023-12-25

- Effect and mechanism of Jianpi Yishen Formula on muscle consumption and survival time in mouse model with lung cancer cachexia
- Beijing Journal of Traditional Chinese Medicine Vol. 42, Issue 11, Pages: 1212-1218(2023)
- 作者机构：
  
  1.中国中医科学院广安门医院血液科，北京 100053
  2.中国中医科学院中医临床基础医学研究所，北京 100091
  3.中国中医科学院针灸研究所，北京 100091
- 作者简介：
- 基金信息：
- DOI：10.16025/j.1674-1307.2023.11.011
  CLC：
扫描看全文
吉兆奕，朱健，朱晓云，等.健脾益肾方对肺癌恶病质小鼠模型肌肉消耗及生存期的影响及机制研究［J］.北京中医药，2023，42（11）：1212-1218.

JI Zhao-yi,ZHU Jian,ZHU Xiao-yun,et al.Effect and mechanism of Jianpi Yishen Formula on muscle consumption and survival time in mouse model with lung cancer cachexia[J]. Beijing Journal of Traditional Chinese Medicine,2023,42(11):1212-1218.
吉兆奕，朱健，朱晓云，等.健脾益肾方对肺癌恶病质小鼠模型肌肉消耗及生存期的影响及机制研究［J］.北京中医药，2023，42（11）：1212-1218. DOI： 10.16025/j.1674-1307.2023.11.011.

JI Zhao-yi,ZHU Jian,ZHU Xiao-yun,et al.Effect and mechanism of Jianpi Yishen Formula on muscle consumption and survival time in mouse model with lung cancer cachexia[J]. Beijing Journal of Traditional Chinese Medicine,2023,42(11):1212-1218. DOI： 10.16025/j.1674-1307.2023.11.011.

摘要

目的,2,建立C57小鼠肺癌恶病质模型，观察健脾益肾方对其肌肉消耗及生存期的影响，并探讨其可能的作用机制。,方法,2,取10只C57BL/6小鼠为正常对照组；剩余小鼠给予腋下注射lewis肺腺癌肿瘤细胞制备肺癌恶病质模型，随机分为模型组、健脾益肾组、甲地孕酮组，各16只。肺癌细胞接种第2天，健脾益肾组以5倍临床等效剂量给予2.3 g/mL健脾益肾方灌胃，0.3 mL/次；甲地孕酮组给予甲地孕酮溶液灌胃，0.3 mL/次；模型组与正常对照组给予同等体积的生理盐水灌胃。各组均1次/d，灌胃直至第60天。给药14 d后每组取10只小鼠以断颈法处死，其余小鼠留存进行生存期观察。对比各组生化指标［白蛋白（ALB）、球蛋白（GLB）、白球比（ALB/GLB），谷丙转氨酶（ALT）、谷草转氨酶（AST），血糖（GLU），血钙（CA）］，脾脏、肝脏质量及腓肠肌质量，血清TNF-α、激活素A（Activin-A）水平，生存期，肌萎缩相关基因（Activin-A、Myostatin、MuRF-1 mRNA）表达，自噬相关基因（AMPK、beclin mRNA）表达。,结果,2,各组体质量比较，差异无统计学意义（,P,>,0.05）。与模型组比较，健脾益肾组、甲地孕酮组肿瘤最大径、瘤重小（,P,<,0.05），且健脾益肾组肿瘤最大径、瘤重小于甲地孕酮组（,P,<,0.05）。与正常对照组比较，模型组GLU、ALB、ALB/GLB低，AST、AST/ALT、CA高（,P,<,0.05）；与模型组比较，健脾益肾组GLU、ALB、ALB/GLB高，AST、AST/ALT、CA低（,P,<,0.05），甲地孕酮组GLU高（,P,<,0.05）；与甲地孕酮组比较，健脾益肾组ALB/GLB高（,P,<,0.05）。与正常对照组比较，模型组脾脏、肝脏质量高，腓肠肌质量低（,P,<,0.05）；与模型组比较，健脾益肾组肝脏质量低（,P,<,0.05），腓肠肌质量高（,P,<,0.05）；与甲地孕酮组比较，健脾益肾组肝脏质量低（,P,<,0.05）。与正常对照组比较，模型组血清TNF-α、Activin-A水平高（,P,<,0.05）；与模型组比较，健脾益肾组、甲地孕酮组血清Activin-A水平低（,P,<,0.05）。与模型组比较，健脾益肾组生存期长（,P,<,0.05）；与模型组比较，甲地孕酮组生存期长，但差异无统计学意义（,P>,0.05）；与甲地孕酮组比较，健脾益肾组生存期长，但差异无统计学意义（,P>,0.05）。与正常对照组比较，模型组Activin-A、Myostatin、MuRF-1 mRNA表达高（,P,<,0.05）；与模型组比较，健脾益肾组、甲地孕酮组Activin-A、Myostatin、MuRF-1 mRNA表达低（,P,<,0.05）；与甲地孕酮组比较，健脾益肾组Activin-A mRNA表达低（,P,<,0.05）。与正常对照组比较，模型组AMPK、beclin mRNA表达高（,P,<,0.05）；与模型组比较，健脾益肾组、甲地孕酮组AMPK、beclin mRNA表达低（,P,<,0.05）；与甲地孕酮组比较，健脾益肾组AMPK mRNA表达低（,P,<,0.05），beclin mRNA表达高（,P,<,0.05）。,结论,2,健脾益肾方能够改善肺癌恶病质小鼠体内炎症环境，抑制其骨骼肌萎缩，延长生存期；其作用机制可能与自噬-溶酶体途径（autophagy-lysosomal pathway，ALS）和泛素-蛋白酶体（ubiquitin-proteasome，UPS）信号途径有关。

Abstract

Objective,2,To establish a model of cachexia of lung cancer in C57 mice and observe the mechanism of Jianpi Yishen（strenghtening spleen and benefiting kidney）Formula on muscle consumption and the survival time of cachexia of lung cancer in order to explore the mechanism.,Methods,2,Ten C57BL/6 mice were randomly selected as normal control group； lewis lung adenocarcinoma tumor cells were injected subcutively into the armpit of C57BL/6 mice to establish tumor cachexia models， which were divided into model group，Jianpi Yishen group and megestrol acetate group of 16 mice in each group.On the second day after the inoculation of lung cancer cells， the Jianpi Yishen group was given 2.3 g/mL Jianpi Yishen recipe by gavage， 0.3 mL/ time， at 5 times the clinical equivalent dose； Megestrol acetate group was given megestrol acetate solution by gavage， 0.3 mL/ time； the model group and the normal control group were given the same volume of normal saline by gavage.Each group was given intragastric administration once a day until the 60th day.After 14 days of administration， 10 mice in each group were killed by neck-breaking， and the remaining mice were kept for survival observation. Biochemical indexes（ALB， GLB，ALB/GLB， ALT， AST，GLU， CA）， Spleen， liver and gastrocnemius mass， serum levels of TNF-α and Activin-A， as well as Activin-A，Myostatin，MuRF-1 mRNA，and expression of AMPK， beclin mRNA were detected.,Results,2,There was no significant difference in body mass among groups （,P,>,0.05）.Compared with the model group， the largest tumor diameter and tumor weight in Jianpi Yishen group and Megestrol acetate group were smaller （,P,<,0.05）， and the largest tumor diameter and tumor weight in Jianpi Yishen group were smaller than those in Megestrol acetate group （,P,<,0.05）. Compared with the normal control group， GLU， ALB and ALB/GLB in the model group were lower， while AST， AST/ALT and CA were higher （,P,<,0.05）. Compared with model group， GLU， ALB， ALB/GLB in Jianpi Yishen group were higher， AST， AST/ALT and CA were lower （,P,<,0.05）， and GLU in Megestrol acetate group was higher （,P,<,0.05）. Compared with megestrol acetate group， the ALB/GLB of Jianpi Yishen group was higher （,P,<,0.05）. Compared with the normal control group， the weight of spleen and liver in the model group was higher， but the weight of gastrocnemius was lower （,P,<,0.05）. Compared with the model group， the quality of liver was lower （,P<,0.05） and the quality of gastrocnemius was higher （,P,<,0.05）. Compared with megestrol acetate group， the quality of liver in Jianpi Yishen group was lower （,P,<,0.05）. Compared with the normal control group， the levels of serum TNF-α and Activin-A in the model group were higher （,P,<,0.05）. Compared with the model group， the serum Activin-A levels in the Jianpi Yishen group and Megestrol acetate group were lower （,P,<,0.05）. Compared with the model group， the survival time of Jianpi Yishen group was longer （,P,<,0.05）. Compared with the model group， the survival time of megestrol acetate group was longer， but the difference was not statistically significant （,P,>,0.05）. Compared with megestrol acetate group， the survival time of Jianpi Yishen group was longer， but the difference was not statistically significant （,P,>,0.05）. Compared with the normal control group， the mRNA expressions of Activin-A， Myostatin and MuRF-1 mRNA the model group were higher （,P,<,0.05）. Compared with the model group， the expressions of Activin-A， Myostatin and MuRF-1 mRNA in the Jianpi Yishen group and Megestrol acetate group were lower （,P,<,0.05）. Compared with megestrol acetate group， the expression of Activin-A mRNA in Jianpi Yishen group was lower （,P,<,0.05）. Compared with the normal control group， the expression of AMPK and beclin mRNA in the model group was higher （,P ,<, 0.05）. Compared with the model group， the expressions of AMPK and beclin mRNA in Jianpi Yishen group and Megestrol acetate group were lower （,P,<, 0.05）. Compared with megestrol acetate group， the expression of AMPK mRNA in Jianpi Yishen group was lower （,P,<,0.05） and beclin mRNA was higher （,P,<,0.05）,Conclusion,2,Jianpi Yishen Formula can improve the inflammatory environment，inhibit skeletal muscle atrophy in mice with lung cancer exoxia and prolong the lifeby regulating the autophagolysosome pathway （ALS） and ubiquitin-proteasome pathway （UPS）.

关键词

肺肿瘤小鼠Lewis细胞肿瘤恶病质自噬-溶酶体途径泛素-蛋白酶体系统健脾益肾方

Keywords

Lung tumormiceLewis cellstumor cachexiaautophagy-lysosomal pathway （ALS） and ubiquitin-proteasome （UPS）Jianpi Yishen Formula

references

BARACOS V, MARTIN L, KORC M, et al. Cancer-associated cachexia[J]. Nat Rev Dis Primers, 2018,4:17105.

PENET MF, BHUJWALLA ZM. Cancer cachexia, recent advances, and future directions[J]. Cancer J, 2015,21(2):117-122.

LOBERG RD, BRADLEY DA, TOMLINS SA, et al. The lethal phenotype of cancer: the molecular basis of death due to malignancy[J]. CA Cancer J Clin, 2007,57(4):225-241.

FEARON K, STRASSER F, ANKER SD, et al. Definition and classification of cancer cachexia: an international consensus[J]. Lancet Oncol, 2011,12(5):489-495.

刘婷, 丁艳, 杨婷婷,等. 鲜枸杞子提取物通过p38MAPK信号通路抑制人肝癌细胞HepG2诱导小鼠恶病质的作用及机制[J]. 中国实验方剂学杂志,2019,25(9):89-94.

王鹂, 邹玺, 刘沈林. 香砂六君汤加减联合甲羟孕酮治疗肿瘤食欲不振：恶病质综合征临床研究[J]. 中国中西医结合杂志,2018,38(8):927-931.

邓哲, 尹周安, 胡玉星. 结合《金匮要略》虚劳病谈肿瘤恶病质的辨治[J]. 中医药导报,2019,25(11):32-34.

吴洁, 刘玉琴, 董继红,等. 健脾益肾方对小鼠移植性前胃癌术后复发转移及生存期的影响[J]. 中西医结合学报,2006,4(5):495-499.

KIM S, WELSH DA, RAVUSSIN E, et al. An elevation of resting metabolic rate with declining health in nonagenarians may be associated with decreased muscle mass and function in women and men, respectively[J]. J Gerontol A Biol Sci Med Sci, 2014,69(6):650-656.

MüLLER MJ, WANG Z, HEYMSFIELD SB, et al. Advances in the understanding of specific metabolic rates of major organs and tissues in humans[J]. Curr Opin Clin Nutr Metab Care, 2013,16(5):501-508.

HEYMSFIELD SB, PETERSON CM, BOURGEOIS B, et al. Human energy expenditure: advances in organ-tissue prediction models[J]. Obes Rev, 2018,19(9):1177-1188.

王新颖,黎介寿.癌性恶病质的代谢改变和营养干预策略[J].肠外与肠内营养,2017,24(1):4-9.

ARGILÉS JM, LÓPEZ-SORIANO FJ, BUSQUETS S. Mediators of cachexia in cancer patients[J]. Nutrition, 2019,66:11-15.

ANDO K, TAKAHASHI F, MOTOJIMA S, et al. Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia[J]. J Clin Oncol, 2013,31(6):e69-72.

HE M, LUO Y, CHEN L, et al. Shashen maidong decoction: the effect of TNF-α and IL-6 on lung cancer cachexia based on cancer toxicity theory[J]. Am J Transl Res, 2021,13(6):6752-6758.

WANG DT, YIN Y, YANG YJ, et al. Resveratrol prevents TNF-α-induced muscle atrophy via regulation of Akt/mTOR/FoxO1 signaling in C2C12 myotubes[J]. Int Immunopharmacol, 2014,19(2):206-213.

KIMURA K, CHENG XW, INOUE A, et al. β-Hydroxy-β-methylbutyrate facilitates PI3K/Akt-dependent mammalian target of rapamycin and FoxO1/3a phosphorylations and alleviates tumor necrosis factor α/interferon γ-induced MuRF-1 expression in C2C12 cells[J]. Nutr Res, 2014,34(4):368-374.

CHEN JL, WALTON KL, QIAN H, et al. Differential effects of IL6 and Activin A in the development of cancer-associated cachexia[J]. Cancer Res, 2016,76(18):5372-5382.

QUEIROZ AL, DANTAS E, RAMSAMOOJ S, et al. Blocking ActRIIB and restoring appetite reverses cachexia and improves survival in mice with lung cancer[J]. Nat Commun, 2022,13(1):4633.

SØRENSEN J. Lung cancer cachexia: can molecular understanding guide clinical management[J]. Integr Cancer Ther, 2018,17(3):1000-1008.

ZHUANG P, ZHANG J, WANG Y, et al. Reversal of muscle atrophy by Zhimu and Huangbai herb pair via activation of IGF-1/Akt and autophagy signal in cancer cachexia[J]. Support Care Cancer, 2016,24(3):1189-1198.

LOUMAYE A, DE BARSY M, NACHIT M, et al. Role of Activin A and myostatin in human cancer cachexia[J]. J Clin Endocrinol Metab, 2015,100(5):2030-2038.

CHIAPPALUPI S, SORCI G, VUKASINOVIC A, et al. Targeting RAGE prevents muscle wasting and prolongs survival in cancer cachexia[J]. J Cachexia Sarcopenia Muscle, 2020,11(4):929-946.

PAUL PK, KUMAR A. TRAF6 coordinates the activation of autophagy and ubiquitin-proteasome systems in atrophying skeletal muscle[J]. Autophagy, 2011,7(5):555-556.

中华医学会肠外肠内营养学分会. 肿瘤患者营养支持指南[J]. 中华外科杂志,2017,55(11):801-829.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of Jianpi Runfu Decoction on skin lesions and cytoinflammatory factors in mice with atopic dermatitis of spleen deficiency syndrome

Effects of different ranges of cold ablation on Lewis lung cancer mouse Tregs cells

Mechanism of Tangluoning for alleviating pyroapoptosis of sciatic nerve cells in diabetic mice by SIRT1

Effect and mechanism of Qingre Jianpi Tiaochang Recipe in DSS-induced colitis model mice

Effect mechanism of Feiliuping Ointment on inhibition of Lewis lung cancer by regulating NF-κB signaling pathway in tumor inflammatory microenvironment

Related Author

No data

Related Institution

Department of Dermatology，Beijing Traditional Chinese Medicine Hospital Affiliated to the Capital Medical University

Beijing University of Chinese Medicine

Department of Oncology，Dongfang Hospital，Beijing University of Chinese Medicine

Clinical Trial Center，Dongfang Hospital，Beijing University of Chinese Medicine

The Second Clinical Medical College of Beijing University of Chinese Medicine

⁰